ArticleJournal of experimental & clinical cancer research : CR2024

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.

Christopher Montemagno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.